MAIA — Maia Biotechnology Share News
0.000.00%
Last trade - 00:00Brief: Maia Biotechnology Reports Second Quarter 2023 Financial Results
Brief: MAIA Biotechnology Reports Updates For THIO-101 Phase 2 Trial
Brief: Maia Biotechnology Reports Updates On Preliminary Survival Data For Thio-101 Phase 2 Trial For Advanced Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Files For Offering Of Up To 2.1 Mln Shares
Brief: MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
Brief: MAIA Biotechnology Reports First Quarter 2023 Financial Results
Brief: Maia Biotechnology, Inc. Says Public Offering Of 2.22 Mln Common Shares Priced At $2.25 Per Share
Brief: Maia Biotechnology Reports Preliminary Survival Data In Part A Of Thio-101 Phase 2 Trial For Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Reports Data From Phase 2 Trial For Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Files For Offering 3.36 Million Shares Of Common Stock - SEC Filing
Brief: Maia Biotechnology Reports Full Year 2022 Financial Results
Brief: Maia Biotechnology Doses First Patients In Europe In Ongoing Phase 2 Trial (Thio-101) Evaluating Thio For Non-Small Cell Lung Cancer Treatment
Brief: MAIA Biotechnology Says Telomere-Targeting Agent THIO Demonstrated Significantly Greater Tumor Inhibition
Brief: Maia Biotechnology Inc Files For Offering Of 2.4 Million Shares Of Common Stock - SEC Filing
Brief: MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
Brief: MAIA Biotechnology Holds Successful Pre-IND Meeting With FDA For Planned U.S. Expansion Of Thio-101 Phase 2 Trial
Brief: MAIA Biotechnology Presents Preclinical Data At SITC Annual Meeting Validating Efficacy Of THIO In Treating Hepatocellular Carcinoma
Brief: Maia Biotechnology Reports Third Quarter 2022 Financial Results
Brief: Maia Biotechnology Reports Second Quarter 2022 Financial Results And Provides Corporate Update